CN112691199A - Marker for predicting response of patient to inhibitor and using method thereof - Google Patents

Marker for predicting response of patient to inhibitor and using method thereof Download PDF

Info

Publication number
CN112691199A
CN112691199A CN202110102919.1A CN202110102919A CN112691199A CN 112691199 A CN112691199 A CN 112691199A CN 202110102919 A CN202110102919 A CN 202110102919A CN 112691199 A CN112691199 A CN 112691199A
Authority
CN
China
Prior art keywords
inhibitor
marker
mixture
prepared
predicting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110102919.1A
Other languages
Chinese (zh)
Inventor
薛佳
钱武斌
毛彬臣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guanke Biotechnology Suzhou Co ltd
Original Assignee
Guanke Biotechnology Suzhou Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guanke Biotechnology Suzhou Co ltd filed Critical Guanke Biotechnology Suzhou Co ltd
Priority to CN202110102919.1A priority Critical patent/CN112691199A/en
Publication of CN112691199A publication Critical patent/CN112691199A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses a marker for predicting the reaction of a patient to an inhibitor and a using method thereof, relates to the technical field of inhibitors, and is prepared from an oxygen group, amino acid, sulfydryl, dichloropyridine, trichlorophenoxy and methoxyphenoxy. The invention has simple production steps, does not need to be prepared at present, can realize mass production, can be directly injected into the stomach of a patient through a medicine applicator, is easy to feed, has simple operation, can help people to adjust the immunity of the people, has the function of strengthening the brain by the aid of the amino acid, and can also play a role in adjusting the blood pressure and be used as a preventive or therapeutic agent for diseases such as heart failure, diabetes and the like.

Description

Marker for predicting response of patient to inhibitor and using method thereof
Technical Field
The invention relates to the technical field of inhibitors, in particular to a marker for predicting the response of a patient to an inhibitor and a using method thereof.
Background
ACEI is a kind of antihypertensive drug widely used in clinical practice at present, and there are many clinical studies related to ACEI for treating hypertension at home and abroad, and people's understanding of the important role of ACEI in treating hypertension or other cardiovascular diseases is continuously improved, and the application of ACEI in treating hypertension is briefly summarized below. The ACEI developed at present can be divided into three main categories according to the difference of zinc ion ligands on ACE. Differences in molecular structure can affect its pharmacokinetic properties such as tissue distribution and clearance patterns, and thus have different effects on various organ functions. Different tissue affinities of various ACEIs result in different clinical effects. The following problems exist in the prior art:
because the inhibitor belongs to a slightly soluble substance, the inhibitor is not soluble in water or most organic solvents, and only soluble in certain acids, so that the application of the inhibitor is greatly limited.
Disclosure of Invention
The technical problem to be solved by the invention is to provide a marker for predicting the reaction of a patient to an inhibitor and a using method thereof, so that the existing preparation is not needed, and the mass production can be realized; can be directly injected into the stomach of a patient through a medicine applicator, is easy to feed and simple to operate, and solves the problem that the application of the inhibitor is greatly limited because the inhibitor belongs to insoluble substances, is not soluble in water or most organic solvents and is only soluble in certain acids.
In order to solve the technical problems, the technical scheme adopted by the invention is as follows: a marker and method of use thereof for predicting a patient's response to an inhibitor is provided:
in a first aspect, the present invention provides a technical solution: a marker for predicting the reaction of a patient to an inhibitor is prepared from oxy, amino acid, sulfydryl, dichloropyridine, trichlorophenoxy and methoxyphenoxy, and comprises the following components in parts by weight:
10g of an oxygen radical, and the like,
12g of amino acid, namely 12g of amino acid,
5.0 to 5.5g of mercapto group,
0.2 to 0.35g of dichloropyridine,
0.8 to 1.2g of trichlorophenoxy,
0.22 to 0.28g of methoxyphenoxy,
the rest is added with water solvent.
Further: the oxygen radical is one or a mixture of more than two of oxygen atom, argon atom, neon atom, helium atom, krypton atom and xenon atom.
Further: the amino acid is one or a mixture of more than two of carbon atoms, hydrogen atoms, oxygen atoms and nitrogen atoms.
Further: the sulfydryl is one or a mixture of more than two of sulfur atom, hydrogen atom, mercaptan, thiocarboxylic acid and thiophenol.
Further: the dichloropyridine is one or a mixture of more than two of clopyralid, aminopyralid, sodium dodecyl benzene sulfonate and alkylphenol polyoxyethylene.
Further: the trichlorophenoxy is one or a mixture of more than two of chlorine, phosphorus trichloride, phosphorus oxychloride and phosphorus pentachloride.
Further: the methoxyphenoxy is one or a mixture of more than two of methoxybenzene, bromoanisole, p-bromoanisole, bromomethoxybenzene, p-methoxybromobenzene and p-bromoanisole.
In a second aspect, the present invention provides a technical solution: a method of using a marker to predict a patient's response to an inhibitor comprising the steps of: s1, taking oxy, amino acid and sulfydryl as raw materials, reacting with propanethiol to prepare 2-nitro-5-propanethioaniline, reducing the aniline and reacting with methyl cyanocarbamate to obtain an inhibitor, and taking the weight of the mixture ratio for later use;
s2, mixing the components according to the weight ratio, taking a small amount of aqueous solvent to mix and stir the amino acid and the sulfydryl according to the ratio, adding the inhibitor prepared in the step S1, and stirring the mixture to obtain a pasty inhibitor for later use;
s3, mixing the above components, dissolving dichloropyridine and trichlorophenoxy respectively in appropriate amount of water solvent, adding into the paste inhibitor prepared in S2, and stirring.
S4, mixing the above materials, dissolving a small amount of water solvent with the mixed methoxyphenoxy group, adding into the pasty inhibitor prepared from S3, and stirring.
S5, shearing the pasty inhibitor prepared in S3 for 20 to 30 minutes under mechanical shearing conditions, adding the rest of the water solvent to the sheared pasty inhibitor, and mechanically shearing for 10 to 20 minutes to obtain a uniform inhibitor liquid.
And S6, filtering, encapsulating and detecting the uniform inhibitor liquid obtained by mechanical shearing in the step S5, sterilizing in a sterilizing chamber at 100 ℃ for 30 minutes, taking out and storing, and further predicting that the marker of the reaction of the patient to the inhibitor is prepared.
The invention has the beneficial effects that: the production steps are simple, no existing preparation is needed, and mass production can be realized; the amino acid injection can be directly injected into the stomach of a patient through a drug administration device, the drug administration device is easy to feed, the operation is simple, the amino acid can help us to adjust the immunity of the person, the amino acid can help us to effectively achieve the effect of strengthening the brain, and part of the amino acid can also play the role of adjusting the blood pressure and can be used as a preventive or therapeutic agent for diseases such as heart failure, diabetes and the like.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The invention provides a technical scheme that: a marker and method of use thereof for predicting patient response to an inhibitor:
in a first aspect, the present invention provides a technical solution: the marker for predicting the reaction of a patient to an inhibitor is a mixture of one or more of oxygen atoms, argon atoms, neon atoms, helium atoms, krypton atoms and xenon atoms, amino acids are a mixture of one or more of carbon atoms, hydrogen atoms, oxygen atoms and nitrogen atoms, sulfydryl is a mixture of one or more of sulfur atoms, hydrogen atoms, mercaptan, thiocarboxylic acid and thiophenol, dichloropyridine is clopyralid, aminopyralid, sodium dodecyl benzene sulfonate, one or more of alkylphenol polyoxyethylene ether, trichlorophenoxy is a mixture of one or more of chlorine, phosphorus trichloride, phosphorus oxychloride and phosphorus pentachloride, and methoxyphenoxy is a mixture of methoxybenzene, bromoanisole, p-bromoanisole, bromoanisole and bromomethoxybenzene, One or more than two of p-methoxy bromobenzene and p-bromo phenyl methyl ether and an aqueous solvent.
Example 1
The weight ratio of each component is as follows:
10 percent of oxygen radical,
12 percent of oxygen atoms,
5.1 percent of carbon atoms,
0.011 percent of sulfur atoms,
0.9 percent of clopyralid,
0.23 percent of chlorine gas,
0.35 percent of methoxybenzene
The rest is added with water solvent.
a. Accurately weighing 12% of oxygen atoms and 5.1% of carbon atoms, dissolving and mixing with a proper amount of water solvent, stirring uniformly, then accurately weighing 10% of oxygen groups, adding into the mixture, mixing and stirring uniformly to form paste;
b. accurately weighing 0.011 percent of sulfur atoms and 0.9 percent of clopyralid, dissolving and mixing the sulfur atoms and the clopyralid by using a proper amount of aqueous solvent, uniformly stirring the mixture, adding the mixture into the a, and uniformly stirring the mixture into paste;
c. accurately weighing 0.23% of chlorine and 0.35% of methoxybenzene, dissolving with a proper amount of water solvent, and adding into b to be uniformly mixed and stirred to form paste;
d. c, putting the prepared c into a mechanical shearing machine for shearing for 20 to 30 minutes, adding the residual water solvent into the sheared pasty inhibitor liquid, and mechanically shearing for 10 to 20 minutes to ensure that the prepared pasty inhibitor liquid is changed into uniform inhibitor liquid;
e. and (3) filling and sealing the mechanically sheared filtering inhibitor liquid, detecting leakage, and sterilizing in a sterilization room at 100 ℃ for 30 minutes to obtain the product.
Example 2
The weight ratio of each component is as follows:
10 percent of oxygen radical,
12 percent of argon atoms,
5.2 percent of hydrogen atoms,
0.012 percent of mercaptan,
1.0 percent of aminopyralid,
0.24 percent of phosphorus trichloride,
0.36 percent of bromoanisole
The rest is added with water solvent.
a. Accurately weighing 12% of argon atoms and 5.2% of hydrogen atoms, dissolving the argon atoms and the 5.2% of hydrogen atoms by using a proper amount of hydrosolvent, mixing and stirring the mixture uniformly, then accurately weighing 10% of oxygen groups, adding the mixture into the mixture, and uniformly mixing and stirring the mixture to form paste;
b. accurately weighing 0.012 percent of mercaptan and 1.0 percent of aminopyralid, dissolving and mixing the mercaptan and the aminopyralid by using a proper amount of hydrosolvent, stirring the mixture evenly, adding the mixture into the mixture a, and stirring the mixture evenly to form paste;
c. accurately weighing 0.24% of phosphorus trichloride and 0.36% of bromoanisole, dissolving the phosphorus trichloride and the 0.36% of bromoanisole by using a proper amount of water solvent, and adding the phosphorus trichloride and the 0.36% of bromoanisole into the mixture b to be uniformly mixed and stirred into paste;
d. c, putting the prepared c into a mechanical shearing machine for shearing for 20 to 30 minutes, adding the residual water solvent into the sheared pasty inhibitor liquid, and mechanically shearing for 10 to 20 minutes to ensure that the prepared pasty inhibitor liquid is changed into uniform inhibitor liquid;
e. and (3) filling and sealing the mechanically sheared filtering inhibitor liquid, detecting leakage, and sterilizing in a sterilization room at 100 ℃ for 30 minutes to obtain the product.
Example 3
The weight ratio of each component is as follows:
10 percent of oxygen radical,
12% of neon atoms,
5.3 percent of oxygen atoms,
0.013 percent of thiocarboxylic acid,
1.1 percent of sodium dodecyl benzene sulfonate,
0.25 percent of phosphorus oxychloride,
p-bromoanisole 0.37%
The rest is added with water solvent.
a. Accurately weighing 12% neon atoms and 5.3% oxygen atoms, dissolving with appropriate amount of water solvent, mixing, stirring, accurately weighing 10% oxygen groups, adding into the mixture, and stirring to obtain paste;
b. accurately weighing 0.013% of thiocarboxylic acid and 1.1% of sodium dodecyl benzene sulfonate, dissolving and mixing with a proper amount of water solvent, uniformly stirring, adding into a, and uniformly stirring to form a paste;
c. accurately weighing 0.25% of phosphorus oxychloride and 0.37% of p-bromoanisole, dissolving the phosphorus oxychloride and the 0.37% of p-bromoanisole in a proper amount of water solvent, and adding the dissolved phosphorus oxychloride and the p-bromoanisole into the mixture b to be uniformly mixed and stirred into paste;
d. c, putting the prepared c into a mechanical shearing machine for shearing for 20 to 30 minutes, adding the residual water solvent into the sheared pasty inhibitor liquid, and mechanically shearing for 10 to 20 minutes to ensure that the prepared pasty inhibitor liquid is changed into uniform inhibitor liquid;
e. and (3) filling and sealing the mechanically sheared filtering inhibitor liquid, detecting leakage, and sterilizing in a sterilization room at 100 ℃ for 30 minutes to obtain the product.
Example 4
The weight ratio of each component is as follows:
10 percent of oxygen radical,
12% of helium atoms,
5.4 percent of nitrogen atoms,
0.014% of thiophenol,
1.2 percent of alkylphenol polyoxyethylene ether,
0.26 percent of phosphorus pentachloride,
the rest is added with water solvent.
a. Accurately weighing 12% of helium atoms and 5.4% of nitrogen atoms, dissolving and mixing uniformly by using a proper amount of hydrosolvent, then accurately weighing 10% of oxygen groups, adding into the mixture, mixing uniformly and stirring to form paste;
b. accurately weighing 0.014% of thiophenol and 1.2% of alkylphenol polyoxyethylene ether, dissolving and mixing with a proper amount of water solvent, stirring uniformly, adding into a, and stirring uniformly to form paste;
c. accurately weighing 0.26% of phosphorus pentachloride, dissolving the phosphorus pentachloride with a proper amount of water solvent, adding the phosphorus pentachloride into the solution b, and uniformly mixing and stirring the solution b to form paste;
d. c, putting the prepared c into a mechanical shearing machine for shearing for 20 to 30 minutes, adding the residual water solvent into the sheared pasty inhibitor liquid, and mechanically shearing for 10 to 20 minutes to ensure that the prepared pasty inhibitor liquid is changed into uniform inhibitor liquid;
e. and (3) filling and sealing the mechanically sheared filtering inhibitor liquid, detecting leakage, and sterilizing in a sterilization room at 100 ℃ for 30 minutes to obtain the product.
In a second aspect, the present invention provides a technical solution: a method of using a marker to predict a patient's response to an inhibitor comprising the steps of:
s1, taking oxy, amino acid and sulfydryl as raw materials, reacting with propanethiol to prepare 2-nitro-5-propanethioaniline, reducing the aniline and reacting with methyl cyanocarbamate to obtain an inhibitor, and taking the weight of the mixture ratio for later use;
s2, mixing the components according to the weight ratio, taking a small amount of aqueous solvent to mix and stir the amino acid and the sulfydryl according to the ratio, adding the inhibitor prepared in the step S1, and stirring the mixture to obtain a pasty inhibitor for later use;
s3, mixing the above components, dissolving dichloropyridine and trichlorophenoxy respectively in appropriate amount of water solvent, adding into the paste inhibitor prepared in S2, and stirring.
S4, mixing the above materials, dissolving a small amount of water solvent with the mixed methoxyphenoxy group, adding into the pasty inhibitor prepared from S3, and stirring.
S5, shearing the pasty inhibitor prepared in S3 for 20 to 30 minutes under mechanical shearing conditions, adding the rest of the water solvent to the sheared pasty inhibitor, and mechanically shearing for 10 to 20 minutes to obtain a uniform inhibitor liquid.
And S6, filtering, encapsulating and detecting the uniform inhibitor liquid obtained by mechanical shearing in the step S5, sterilizing in a sterilizing chamber at 100 ℃ for 30 minutes, taking out and storing, and further predicting that the marker of the reaction of the patient to the inhibitor is prepared.
The invention has the beneficial effects that: the production steps are simple, no existing preparation is needed, and mass production can be realized; the amino acid injection can be directly injected into the stomach of a patient through a drug administration device, the drug administration device is easy to feed, the operation is simple, the amino acid can help us to adjust the immunity of the person, the amino acid can help us to effectively achieve the effect of strengthening the brain, and part of the amino acid can also play the role of adjusting the blood pressure and can be used as a preventive or therapeutic agent for diseases such as heart failure, diabetes and the like.
The present invention has been described in general terms in the foregoing, but it will be apparent to those skilled in the art that modifications and improvements can be made thereto based on the present invention. Therefore, modifications or improvements are within the scope of the invention without departing from the spirit of the inventive concept.

Claims (8)

1. A marker for predicting patient response to an inhibitor, comprising: the marker for predicting the reaction of the patient to the inhibitor is prepared from oxy, amino acid, sulfydryl, dichloropyridine, trichlorophenoxy and methoxyphenoxy, and the weight ratio of each component is as follows:
10g of an oxygen radical, and the like,
12g of amino acid, namely 12g of amino acid,
5.0 to 5.5g of mercapto group,
0.2 to 0.35g of dichloropyridine,
0.8 to 1.2g of trichlorophenoxy,
0.22 to 0.28g of methoxyphenoxy,
the rest is added with water solvent.
2. A marker for predicting patient response to an inhibitor according to claim 1, wherein: the oxygen radical is one or a mixture of more than two of oxygen atom, argon atom, neon atom, helium atom, krypton atom and xenon atom.
3. A marker for predicting patient response to an inhibitor according to claim 1, wherein: the amino acid is one or a mixture of more than two of carbon atoms, hydrogen atoms, oxygen atoms and nitrogen atoms.
4. A marker for predicting patient response to an inhibitor according to claim 1, wherein: the sulfydryl is one or a mixture of more than two of sulfur atom, hydrogen atom, mercaptan, thiocarboxylic acid and thiophenol.
5. A marker for predicting patient response to an inhibitor according to claim 1, wherein: the dichloropyridine is one or a mixture of more than two of clopyralid, aminopyralid, sodium dodecyl benzene sulfonate and alkylphenol polyoxyethylene.
6. A marker for predicting patient response to an inhibitor according to claim 1, wherein: the trichlorophenoxy is one or a mixture of more than two of chlorine, phosphorus trichloride, phosphorus oxychloride and phosphorus pentachloride.
7. A marker for predicting patient response to an inhibitor according to claim 1, wherein: the methoxyphenoxy is one or a mixture of more than two of methoxybenzene, bromoanisole, p-bromoanisole, bromomethoxybenzene, p-methoxybromobenzene and p-bromoanisole.
8. A method of using a marker to predict patient response to an inhibitor, comprising: the marker for predicting the response of a patient to an inhibitor and the using method thereof comprise the following steps:
s1, taking oxy, amino acid and sulfydryl as raw materials, reacting with propanethiol to prepare 2-nitro-5-propanethioaniline, reducing the aniline and reacting with methyl cyanocarbamate to obtain an inhibitor, and taking the weight of the mixture ratio for later use;
s2, mixing the components according to the weight ratio, taking a small amount of aqueous solvent to mix and stir the amino acid and the sulfydryl according to the ratio, adding the inhibitor prepared in the step S1, and stirring the mixture to obtain a pasty inhibitor for later use;
s3, mixing the components according to the weight ratio, dissolving the mixed dichloropyridine and trichlorophenoxy respectively by using a proper amount of aqueous solvent, adding the mixture into the pasty inhibitor prepared in the S2, and stirring the mixture uniformly while adding;
s4, mixing the components according to the weight, taking a small amount of hydrosolvent, dissolving the mixed methoxyphenoxy, adding the dissolved methoxyphenoxy into the pasty inhibitor prepared by the S3, and stirring the mixture uniformly;
s5, shearing the pasty inhibitor prepared in S3 for 20 to 30 minutes under mechanical shearing conditions, adding the rest of the water solvent to the sheared pasty inhibitor, and mechanically shearing for 10 to 20 minutes to make the prepared pasty inhibitor become a uniform inhibitor liquid;
and S6, filtering, encapsulating and detecting the uniform inhibitor liquid obtained by mechanical shearing in the step S5, sterilizing in a sterilizing chamber at 100 ℃ for 30 minutes, taking out and storing, and further predicting that the marker of the reaction of the patient to the inhibitor is prepared.
CN202110102919.1A 2021-01-26 2021-01-26 Marker for predicting response of patient to inhibitor and using method thereof Pending CN112691199A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110102919.1A CN112691199A (en) 2021-01-26 2021-01-26 Marker for predicting response of patient to inhibitor and using method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110102919.1A CN112691199A (en) 2021-01-26 2021-01-26 Marker for predicting response of patient to inhibitor and using method thereof

Publications (1)

Publication Number Publication Date
CN112691199A true CN112691199A (en) 2021-04-23

Family

ID=75516175

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110102919.1A Pending CN112691199A (en) 2021-01-26 2021-01-26 Marker for predicting response of patient to inhibitor and using method thereof

Country Status (1)

Country Link
CN (1) CN112691199A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105408498A (en) * 2013-05-24 2016-03-16 4Sc股份公司 Gene expression biomarkers and their use for diagnostic and prognostic application in patients potentially in need of hdac inhibitor treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105408498A (en) * 2013-05-24 2016-03-16 4Sc股份公司 Gene expression biomarkers and their use for diagnostic and prognostic application in patients potentially in need of hdac inhibitor treatment

Similar Documents

Publication Publication Date Title
US8362256B2 (en) Salts of N-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-3-pyridinecarboxamide
EP0188040B1 (en) Slow release solid preparation
CN105287362A (en) Thermally induced hydrogel containing selenium or tellurium, and preparation method and applications thereof
WO1990005713A1 (en) Calcium supplementation by dicalcium citrate-lactate
CN112691199A (en) Marker for predicting response of patient to inhibitor and using method thereof
CN107126431A (en) Xiyanping Neulized inhalation pharmaceutical solutions and preparation method thereof
CN114195851B (en) Compound for preventing and treating liver diseases and pharmaceutical composition thereof
CN110403935A (en) A kind of inhibitors of phosphodiesterase-4 pharmaceutical composition and preparation method thereof for treating canker sore
CN106074431A (en) A kind of Vonoprazan fumarate preparation and application thereof
CN102697749B (en) The preparation method of Benazepril hydrochloride contents in tablets
CN116270443A (en) Fu Nuola raw fumaric acid injection and preparation method thereof
CN103623413B (en) Preparation method and application of controlled release carrier material of sucrose ester
CN110302389B (en) Anti-angiogenesis hydrogel sustained-release preparation and application thereof
CN101327206B (en) Docetaxel injection and preparation method thereof
CN108403619B (en) Medicinal gel preparation for treating skin burn caused by hydrofluoric acid
CN109394712B (en) A kind of valsartan amlodipine composite tablet and preparation method thereof
CN110200905A (en) A kind of ambroxol hydrochloride composition and its injection and application
CN101269042A (en) Enalapril maleate sustained-release dropping pill and preparation method thereof
CN115212171B (en) Ticagrelor sustained-release pellet and pharmaceutical preparation containing same
CN104840444B (en) It is a kind of to be used to treat pharmaceutical preparation of osteoporosis and preparation method thereof
CN107823208A (en) Morpholine kind compound is preparing the application in treating and preventing kidney fibrosis medicine
CN106667954A (en) Diacerein soft capsule preparation and preparation process thereof
KR20130047262A (en) Composition containing ascorbic acid for oral administration with controlled release property and method of analyzing the same
CN111110697A (en) Sodium phosphate powder and preparation method thereof
CN100390184C (en) Sodium menadiol diphosphate ester and its pharmaceutical formulation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210423